Clinical Trials
2
Active:1
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)A First in Human Study to Evaluate the Safety and Immune Response to a Vaccine for the Treatment of a Respiratory Virus, When Administered Into the Arm in Healthy Adult Participants
Phase 1
Completed
- Conditions
- Respiratory Syncytial Virus Infections
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2021-04-21
- Lead Sponsor
- Advaccine (Suzhou) Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT04851977
- Locations
- 🇦🇺
Advanced Vaccine Laboratories Pty Ltd, Melbourne, Victoria, Australia
Safety and Efficacy of BARS13 in the Elderly
Phase 2
Active, not recruiting
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Drug: Recombinant Respiratory Syncytial Virus Vaccine (BARS13)Drug: PlaceboDrug: Recombinant Respiratory Syncytial Virus Vaccine (BARS13) /placebo
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Advaccine (Suzhou) Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 125
- Registration Number
- NCT04681833
- Locations
- 🇦🇺
Q-Pharm Pty Ltd, Herston, Queensland, Australia
🇦🇺CMAX Clinical Research, Adelaide, South Australia, Australia
News
No news found